MK-8527
- Generic Name
- MK-8527
A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012)
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06893081
- Locations
- 🇺🇸
Celerion ( Site 0001), Tempe, Arizona, United States
A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 20
- Registration Number
- NCT06816043
- Locations
- 🇺🇸
Celerion ( Site 0001), Lincoln, Nebraska, United States
A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)
- Conditions
- Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
- Interventions
- Drug: LNG/EE
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT06783192
- Locations
- 🇺🇸
QPS-MRA, LLC-Early Phase (Site 0001), South Miami, Florida, United States
A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT06580587
- Locations
- 🇺🇸
University of Pittsburgh Medical Center Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT06295796
- Locations
- 🇺🇸
Research by Design ( Site 0001), Chicago, Illinois, United States
Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)
- Conditions
- HIVHIV Pre-exposure Prophylaxis
- Interventions
- Drug: Placebo to MK-8527
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 352
- Registration Number
- NCT06045507
- Locations
- 🇺🇸
University of Pittsburgh Medical Center-Division of Infectious Diseases ( Site 0041), Pittsburgh, Pennsylvania, United States
🇿🇦Wits RHI-Wits RHI Ward 21 Clinical Research site ( Site 0027), Johannesburg, Gauteng, South Africa
🇿🇦Helen Joseph Hospital ( Site 0024), Johannesburg, Gauteng, South Africa
MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 20
- Registration Number
- NCT05494736
- Locations
- 🇷🇴
ARENSIA Exploratory Medicine-Institutul National de Boli Infectioase Matei Bals ( Site 0004), București, Bucuresti, Romania
🇿🇦Desmond Tutu Health Foundation ( Site 0001), Cape Town, Western Cape, South Africa
🇿🇦Josha Research ( Site 0003), Bloemfontein, Free State, South Africa
A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 17
- Registration Number
- NCT03615183
- Locations
- 🇷🇴
Matei Bals Infectious Diseases Institute ( Site 0001), Bucharest, Romania
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.